NCT07349901 Predicting Hospital Readmission for Surgical Patients Using Deep Learning Models With Smart Watch and Smart Ring Sensors Data
| NCT ID | NCT07349901 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Getúlio Vargas University Hospital |
| Condition | Patient Readmission |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2026-03-04 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2026-03-04 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hospital readmissions are an important measure of healthcare quality and safety. These events create a substantial burden for patients, families, and health systems because they may increase costs, extend recovery time, and lead to more serious postoperative complications. Predicting which patients are at higher risk of readmission remains difficult, as many complications begin silently and are not easily identified in routine clinical evaluations. This study aims to evaluate whether artificial intelligence (AI) can help predict hospital readmissions in surgical patients by analyzing physiological and behavioral data collected before and after surgery. To achieve this, participants will use wearable devices-specifically a smartwatch and a smart ring-capable of continuously monitoring health biomarkers such as heart rate, electrocardiogram (ECG), oxygen saturation, sleep patterns, blood pressure trends, body composition through bioimpedance, and stress indicators. These devices are provided through a technology partnership and sponsorship from Samsung, which supports the study with advanced health technologies. This is a prospective, single-center cohort study conducted at the main tertiary hospital in the state of Amazonas. Approximately 225 to 300 adults undergoing medium- or large-scale elective surgeries will be invited to participate over a 25-month period. All participants will provide informed consent. After enrollment, the study will collect demographic information, preoperative assessments, validated sleep questionnaires, comorbidity indexes such as the Charlson Comorbidity Index, laboratory exams, pulmonary function tests, intraoperative and postoperative data, and hospital discharge information. Participants will be continuously monitored using wearable devices during their hospital stay-including the first 48 hours in the intensive care unit when applicable-and for 30 days after hospital discharge. These physiological data will be integrated with clinical and laboratory information to create a comprehensive dataset. The primary objective is to develop and test artificial intelligence models capable of predicting 30-day hospital readmission following elective surgery. Both deep learning approaches and classical machine-learning techniques will be evaluated. By analyzing large volumes of continuous physiologic data, these models may identify early signs of postoperative deterioration that would otherwise go unnoticed. If successful, this study may improve postoperative care, support earlier clinical intervention, reduce complications, and help healthcare teams provide safer recovery pathways for surgical patients.
Eligibility Criteria
Inclusion Criteria: * Adults over 18 years of age; * Hospitalization for medium and/or large elective surgery at HUGV; * Conscious and oriented patients who have sufficient understanding to answer questionnaires and use wearable devices for the study; * Have minimal skills in the use of wearable technologies; * Patients who have agreed to participate voluntarily in the research by signing the Informed Consent Form (ICF). Non-inclusion Criteria: * Presence of tattoos or any other skin condition (skin pathologies or skin diseases such as vitiligo, lupus, and atopic dermatitis, among others) that affects the area of the wrist or finger where the wearable sensors are located; * Presence of any type of sensitivity or allergic reaction, of any degree, to the materials of the wearables (smartwatch and smartring); * Pregnant and lactating women; * Participants with implantable cardiac devices, such as pacemakers, cardioverter defibrillators, and resynchronization devices; * Participants in drugs abuse; Exclusion Criteria: * Severe medical conditions and decompensations prior to surgery; * Patients who die before hospital discharge; * Patients with an expected postoperative hospital stay of more than 10 days.
Contact & Investigator
Maria Elizete de Almeida Araújo, Doctor of Health Science
STUDY DIRECTOR
Getúlio Vargas University Hospital
Frequently Asked Questions
Who can join the NCT07349901 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Patient Readmission. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07349901 currently recruiting?
Yes, NCT07349901 is actively recruiting participants. Contact the research team at robsonamorim@ufam.edu.br for enrollment information.
Where is the NCT07349901 trial being conducted?
This trial is being conducted at Manaus, Brazil.
Who is sponsoring the NCT07349901 clinical trial?
NCT07349901 is sponsored by Getúlio Vargas University Hospital. The principal investigator is Maria Elizete de Almeida Araújo, Doctor of Health Science at Getúlio Vargas University Hospital. The trial plans to enroll 300 participants.